UK – NICE publishes final guidance backing Teva’s Ajovy for migraine

The National Institute for Health and Care Excellence (NICE) has now published final guidelines endorsing the NHS use of Teva’s Ajovy (fremanezumab) to prevent migraine.

The decision means use of the drug will be funded by the NHS in adults with chronic migraine who have not responded to at least three prior preventive treatments.

In this subset of patients, clinical trial evidence shows that Ajovy works better than best supportive care in both episodic and chronic migraine. However, it is unclear if fremanezumab works better than botulinum toxin type A, NICE said.

The anti-CGRP preventive therapy is the first of-its-kind to be recommended by the Institute, offering monthly or quarterly dosing options, with the choice to self-inject once patients are trained…